CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Business

Esperion Files For $70M IPO

View Comments
Esperion Therapeutics

Get Breaking News First

Receive News, Politics, and Entertainment Headlines Each Morning.
Sign Up

PLYMOUTH (WWJ) — Plymouth-based Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission.

Esperion is seeking to raise up to $70 million.

Esperion is focused on drugs to treat high levels of low-density lipoprotein cholesterol, the so-called bad cholesterol, that can be taken in pill form, and which offer better side effect profiles than current statin drugs.

The company plans to list its shares on the Nasdaq stock market under the symbol ESPR. Credit Suisse AG and Citigroup Inc. are lead managers on the offering, which has yet to be priced.

The initial Esperion was founded in 1998 and sold to Pfizer Inc. in 2004 for $1.3 billion, but its product — which used a different mechanism of action to raise high-density lipoprotein, the so-called good cholesterol — was never developed for the market. Pfizer later sold the name Esperion and rights to some possible future products back to Roger Newton, who founded the original Esperion.

Esperion announced two weeks ago that it had closed on a $33 million venture funding round.

More at www.esperion.com.

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 1,913 other followers